FibroGen
(Redirected from Fibrogen)
Jump to navigation
Jump to search
| This article is a stub. You can help by expanding it. |
"FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs." [1]
- Thomas B. Neff - Chairman, Founder, Chief Executive Officer
Board
Accessed December 2010: [2]
- Thomas B. Neff - Chairman, Founder, Chief Executive Officer
- Thomas F. Kearns, Jr. - Retired Partner, Bear, Stearns & Co., Inc.
- Kalevi Kurkijärvi - Senior Partner, Chairman and CEO, BioFund Management Fund Ltd.
- Miguel Madero - Fomento Direccion, Mexico
- Rory B. Riggs - Managing Member, Balfour LLC; Former President and Director, Biomatrix, Inc.
- Roberto Pedro Rosenkranz - Chairman and Chief Executive Officer, ROXRO PHARMA, Inc.; Director, Pherin Pharmaceuticals
- Jorma Routti - Chairman of the Board of Directors, FibroGen Europe, Former Director General of the Directorate of Science, Research and Development of the European Commission
- James A. Schoeneck - CEO and Director, BrainCells Inc.
- Julian N. Stern - Counsel to Goodwin Procter, LLP.
- Toshinari Tamura - Former Representative Director, Executive Vice President and Chief Science Officer of Astellas Pharma, Inc.
